PASSAGE BIO INC. - CO

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

18 May 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

09 May 2022 07:00:01 By Nasdaq GlobeNewswire

UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

03 May 2022 14:13:24 By Nasdaq GlobeNewswire

Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

02 May 2022 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

22 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Participate in Upcoming Investor Conferences

28 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

15 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

10 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Participate in Upcoming March Investor Conferences

01 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

24 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

11 Feb 2022 11:00:00 By Nasdaq GlobeNewswire

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

31 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

17 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces Pipeline Expansion and Clinical Program Update

08 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

19 Nov 2021 16:00:00 By Nasdaq GlobeNewswire